SHPL-49
/ Hutchmed
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 07, 2026
SAIL: Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
(clinicaltrials.gov)
- P3 | N=1096 | Recruiting | Sponsor: Shanghai Hutchison Pharmaceuticals Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Ischemic stroke
January 05, 2026
Salidroside derivative SHPL-49 accelerates cutaneous wound healing in diabetic mice by modulating macrophage-mediated TGF-β1/Smad2/3 signaling pathway.
(PubMed, Toxicol Appl Pharmacol)
- "Collectively, our findings suggest that SHPL-49 is a promising therapeutic candidate for diabetic wound healing, functioning through a macrophage-to-fibroblast signaling axis: it polarizes macrophages toward an M2 phenotype, which subsequently release TGF-β1 to enhance fibroblast function via the Smad2/3 signaling pathway. This study establishes a theoretical foundation for the future exploration and development of novel therapeutic indications for SHPL-49."
Journal • Preclinical • Diabetes • Metabolic Disorders • MRC1 • TGFB1
November 22, 2025
SAIL: Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
(clinicaltrials.gov)
- P3 | N=1096 | Not yet recruiting | Sponsor: Shanghai Hutchison Pharmaceuticals Limited
New P3 trial • Cardiovascular • Ischemic stroke
1 to 3
Of
3
Go to page
1